Tiotropium

also known as Tiotropium Bromide · Spiriva · Spiriva Handihaler · TIO · Spiriva Respimat · Tiotropium Bromide Monohydrate · Ba679BR · Bromuro de Tiotropio · +12 more

Other / unclassified

Developed for: chronic obstructive pulmonary disease · asthma · cystic fibrosis · childhood onset asthma · chronic bronchitis · allergic asthma · bronchitis · obstructive lung disease
+3 more
· pulmonary emphysema · spinal cord injury · bronchiectasis
Investigated by: Boehringer Ingelheim · Pfizer · GlaxoSmithKline · Novartis Pharmaceuticals · 3M · Solventum US LLC
+65 more
· AstraZeneca · Novartis · University of Dundee · University of Saskatchewan · Baim Institute for Clinical Research · Brigham and Women's Hospital · Milton S. Hershey Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · Orion Corporation, Orion Pharma · Quotient Clinical · Tenovus Scotland · Teva Branded Pharmaceutical Products R&D, Inc. · Theravance Biopharma · American Academy of Family Physicians National Research Network · Assiut University · Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS · Carelon Research · Centre Hospitalier Universitaire de Besancon · Children's Hospital Medical Center, Cincinnati · Erasme University Hospital · Federal State Budgetary Institution, Pulmonology Scientific Research Institute · Federal University of São Paulo · Franciscus Gasthuis · Fraunhofer-Institute of Toxicology and Experimental Medicine · Guangzhou Institute of Respiratory Disease · Hamilton Health Sciences Corporation · Helsinki University Central Hospital · Henan University of Traditional Chinese Medicine · Huashan Hospital · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · IRCCS Azienda Ospedaliero-Universitaria di Bologna · Imperial College London · Irmandade Santa Casa de Misericórdia de Porto Alegre · James J. Peters Veterans Affairs Medical Center · Kindeva Drug Delivery · Laval University · Massachusetts General Hospital · Mayo Clinic · Medical University of Bialystok · Moscow State University of Medicine and Dentistry · Mylan Inc. · NHS Greater Glasgow and Clyde · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Nemours Children's Clinic · Nephron Pharmaceuticals Corporation · Neutec Ar-Ge San ve Tic A.Ş · Olmsted Medical Center · Parexel · Pearl Therapeutics, Inc. · Queen's University · RWTH Aachen University · Rho, Inc. · Royal Free and University College Medical School · Seoul National University Hospital · Shanghai Zhongshan Hospital · Simbec Research · Taipei Veterans General Hospital, Taiwan · Tanta University · ThomasTruncale · University Hospital, Bordeaux · University Hospital, Ghent · Università degli Studi di Ferrara · Viatris Inc. · Wake Forest University Health Sciences · Yonsei University

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Trimbow	—	2017-07-17	europa.eu ↗
Label expansion	US (FDA)	SPIRIVA RESPIMAT	—	2017-02-15	fda.gov ↗
Label expansion	US (FDA)	SPIRIVA	—	2009-12-17	fda.gov ↗
Approved	US (FDA)	SPIRIVA	—	2004-01-30	fda.gov ↗

Trials 193 · started per year

today

US approved 2004

EU approved 2017

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05748977	Feb 2023 → Feb 2024	chronic obstructive pulmonary disease	Assiut University	Unknown	No outcome recorded
Phase 0	NCT03155204	Apr 2017 → Jan 2018	—	Solventum US LLC	Completed	No outcome recorded
Phase 0	NCT00870896	Feb 2008 → Feb 2009	chronic bronchitis	ThomasTruncale	Completed	No outcome recorded
Phase 123 trials
Phase 1	NCT05246046	Feb → Aug 2022	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03945344	May → Jun 2019	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03246581	Jul 2017 → Jan 2018	—	Kindeva Drug Delivery	Completed	No outcome recorded
Phase 1	NCT02969317	Feb → Jun 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03302065	May → Sep 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02676297	Jan → May 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02627625	Nov 2015 → Mar 2016	—	Solventum US LLC	Completed	No outcome recorded
Phase 1	NCT02573155	Oct 2015 → Aug 2016	asthma, chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02441114	Jul → Oct 2015	chronic obstructive pulmonary disease	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT01703845	Oct 2012 → Mar 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01309139	Mar → Jun 2011	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00555022	Dec 2007 → Apr 2008	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02259959	Apr → Sep 2007	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172534	Sep 2006 → Sep 2008	cystic fibrosis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02259946	Apr → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02254174	Mar → Jul 2006	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00279019	Dec 2005 → Jun 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00257452	Oct 2004 → Jul 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02263976	Aug 2003 → Jun 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172781	Jan → Apr 2001	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172417	Jul → Nov 2000	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02177305	Oct → Dec 1998	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02172339	Apr → Dec 1998	impaired renal function disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT01785433	Jan → Jul 2013	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 231 trials
Phase 2	NCT04990167	Jan 2022 → Oct 2025	childhood onset asthma	Nemours Children's Clinic	Terminated	No outcome recorded
Phase 2	NCT04780984	Nov 2020 → Apr 2021	chronic obstructive pulmonary disease	Nephron Pharmaceuticals Corporation	Completed	No outcome recorded
Phase 2	NCT04179461	Mar 2018 → Oct 2019	childhood onset asthma	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT02203474	Aug 2014	chronic obstructive pulmonary disease	Teva Branded Pharmaceutical Products R&D, Inc.	Withdrawn	No outcome recorded
Phase 2	NCT02586649	Jul 2014 → Dec 2019	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 2	NCT02030535	Jan → Jun 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01696071	Sep 2012 → Jun 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01634113	Jul 2012 → Dec 2014	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01383499	Aug 2011 → Sep 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01233284	Nov 2010 → Jan 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01172925	Nov 2010 → Jun 2016	non-small cell lung carcinoma	Hamilton Health Sciences Corporation	Unknown	No outcome recorded
Phase 2	NCT01222533	Oct 2010 → Nov 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01152450	Jul 2010 → Aug 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01122680	May 2010 → Apr 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT01040403	Jan 2010 → Feb 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00737100	Sep 2008 → Apr 2010	cystic fibrosis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00696020	Jun 2008 → Feb 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00557700	Jan 2008 → May 2010	asthma	University Hospital, Ghent	Completed	No outcome recorded
Phase 2	NCT00528996	Sep 2007 → May 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00422604	Oct 2006 → May 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00365560	Aug 2006 → Nov 2007	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00350207	Jul 2006 → Sep 2008	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00292448	Feb 2006 → Mar 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00325169	Dec 2005 → Aug 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00128440	Aug 2005 → Sep 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242266	Jul 2005 → Jun 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00122434	Jul 2005 → May 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242253	Sep 2003 → Jul 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02238119	Feb → Aug 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02172352	Jul 1998 → May 1999	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02175342	Mar 1998 → Apr 1999	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT03358147	Dec 2017 → Sep 2019	asthma	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 369 trials
Phase 3	NCT05927155	Jun 2021 → Mar 2022	chronic obstructive pulmonary disease	Erasme University Hospital	Completed	No outcome recorded
Phase 3	NCT03169504	May 2017 → May 2018	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT03095456	Mar → Nov 2017	chronic obstructive pulmonary disease	Mylan Inc.	Completed	No outcome recorded
Phase 3	NCT02796677	Jul 2016 → Jun 2017	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT02683668	Feb 2016 → Jan 2018	chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 3	NCT02066298	Jul 2014 → May 2018	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT02085161	Mar 2014 → Aug 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02006732	Nov 2013 → Oct 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01969721	Oct 2013 → Jan 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01634152	Jul 2012 → May 2015	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01634139	Jul 2012 → Jun 2015	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01559116	Mar 2012 → Aug 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01533935	Feb 2012 → Nov 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01536262	Feb 2012 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01525615	Feb 2012 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01431274	Sep 2011 → Sep 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01431287	Sep 2011 → Nov 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01340209	Apr 2011 → Apr 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01290874	Mar 2011 → Jul 2013	asthma	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 3	NCT01316380	Mar 2011 → Apr 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01277523	Jan 2011 → Oct 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01257230	Dec 2010 → Dec 2013	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01179347	Sep 2010 → Mar 2012	cystic fibrosis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01172808	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01172821	Aug 2010 → Nov 2012	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01119937	May 2010 → Nov 2011	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01012765	Nov 2009 → Jan 2011	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00999908	Oct 2009 → Mar 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00776984	Oct 2008 → Jul 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00772538	Oct 2008 → Jul 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00565266	May 2008 → May 2010	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00673478	May 2008 → Jun 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00662792	Apr 2008 → Jul 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00668772	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00615459	Feb → Dec 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00387088	Sep 2006 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00144326	Jul 2003 → Oct 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00239460	Jul 2003 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00239434	Jun 2003 → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00168831	Feb 2003 → Jun 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00168844	Jan 2003 → Jun 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00144339	Dec 2002 → Feb 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00239447	Nov 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00157235	Sep 2002 → Apr 2006	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274092	Sep 2002 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00281567	Aug 2002 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274040	Jul 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274560	May 2002 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172794	May 2002 → Oct 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172456	May → Oct 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274053	Apr 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274573	Mar → Oct 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00277264	Jan 2002 → May 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274547	Sep 2001 → Feb 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172443	Jun 2001 → May 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274521	May 2001 → Feb 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172469	May 2001 → Apr 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274027	Jan 2001 → Mar 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274534	Dec 2000 → Jul 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172807	Dec 2000 → Sep 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172391	Nov 2000 → Aug 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274508	Oct 2000 → Jan 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00274014	Oct 2000 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172430	Sep 2000 → May 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172378	May 2000 → Jan 2002	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172300	Jun 1999 → Nov 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02173691	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172287	Feb 1999 → May 2000	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02172326	Feb → Sep 1998	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 458 trials
Phase 4	NCT06679465	Jan 2025 → Jan 2027 expected	asthma	University of Saskatchewan	Not yet recruiting	No outcome recorded
Phase 4	NCT05165485	Jan 2022 → Nov 2023	chronic obstructive pulmonary disease	Theravance Biopharma	Completed	No outcome recorded
Phase 4	NCT04648813	Nov 2020 → Apr 2021	allergic asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT04231214	Jan 2020 → Apr 2023	chronic obstructive pulmonary disease	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
Phase 4	NCT04223843	Jan → Sep 2020	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03964207	Nov 2019 → Oct 2021	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03662711	Nov 2018 → Oct 2022	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Terminated	No outcome recorded
Phase 4	NCT03478683	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03478696	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03474081	Mar 2018 → Jul 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03219866	Oct 2017 → Apr 2020	chronic obstructive pulmonary disease	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 4	NCT03265145	Sep 2017 → Sep 2020	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03240575	Aug 2017 → Apr 2019	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03055988	Mar 2017 → Mar 2018	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02813200	Jan 2017 → Feb 2019	chronic obstructive pulmonary disease	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 4	NCT03425617	Jan 2017 → Jun 2018	chronic obstructive pulmonary disease	Queen's University	Completed	No outcome recorded
Phase 4	NCT02812862	Aug 2016 → Aug 2017	chronic obstructive pulmonary disease	RWTH Aachen University	Withdrawn	No outcome recorded
Phase 4	NCT02799784	Jul 2016 → Apr 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02682862	Jul 2016 → May 2019	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02567214	Jun 2016 → Nov 2018	chronic obstructive pulmonary disease	Laval University	Completed	No outcome recorded
Phase 4	NCT03199976	Apr 2016 → Nov 2020	asthma, bronchitis, obstructive lung disease	Helsinki University Central Hospital	Terminated	No outcome recorded
Phase 4	NCT02872090	Mar 2016 → Jun 2021	chronic obstructive pulmonary disease	Centre Hospitalier Universitaire de Besancon	Completed	No outcome recorded
Phase 4	NCT02622243	Nov 2015 → Mar 2016	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT02541006	Nov 2014 → Apr 2015	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT04520230	Oct 2014 → Dec 2019	chronic obstructive pulmonary disease	Tanta University	Completed	No outcome recorded
Phase 4	NCT02546349	Jul 2014 → Dec 2015	chronic obstructive pulmonary disease	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT02125734	Apr 2014 → Jan 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02039011	Feb 2014 → Jul 2016	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01959516	Feb → Oct 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01922271	Aug 2013 → Jan 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01693003	Mar → Oct 2013	chronic obstructive pulmonary disease	Irmandade Santa Casa de Misericórdia de Porto Alegre	Completed	No outcome recorded
Phase 4	NCT01794780	Feb 2013 → May 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01762800	Feb 2013 → Sep 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01656005	Aug 2012 → Jul 2016	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01644734	Nov 2011 → Mar 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01483625	Nov 2011 → Dec 2012	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01397890	Jul 2011 → Jun 2013	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT01465906	Nov 2010 → Nov 2011	chronic obstructive pulmonary disease	Shanghai Zhongshan Hospital	Unknown	No outcome recorded
Phase 4	NCT01112241	Apr → May 2010	transplant-related bronchiolitis obliterans	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Completed	No outcome recorded
Phase 4	NCT00783250	Sep 2008 → Aug 2011	chronic obstructive pulmonary disease	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Terminated	No outcome recorded
Phase 4	NCT00680056	Nov 2007 → Dec 2008	chronic bronchitis, pulmonary emphysema	Federal University of São Paulo	Completed	No outcome recorded
Phase 4	NCT00530842	Sep 2007 → Jan 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00525512	Aug 2007 → Jun 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00523991	Apr 2007 → Jul 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00388882	Oct 2006 → Oct 2007	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00578968	Oct 2006 → Aug 2008	chronic obstructive pulmonary disease	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT00359788	Jul 2006 → Apr 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00335621	Jun 2006 → Dec 2007	chronic obstructive pulmonary disease	NHS Greater Glasgow and Clyde	Withdrawn	No outcome recorded
Phase 4	NCT00152984	Dec 2004 → Apr 2006	asthma, chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00106821	Jun 2004 → Aug 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00144196	Mar 2004 → Jul 2005	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02172508	Jan → Mar 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00239499	Sep 2003 → Aug 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361959	Jun 2003 → Feb 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239408	Dec 2002 → Apr 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00274079	Oct 2002 → Oct 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00405236	Oct 2002 → Jan 2005	chronic obstructive pulmonary disease	Royal Free and University College Medical School	Completed	No outcome recorded

Phase not applicable7 trials
—	NCT07541378	Mar 2024 → Feb 2025	chronic obstructive pulmonary disease	Medical University of Bialystok	Suspended	No outcome recorded
—	NCT05495698	Dec 2022 → Dec 2026 expected	chronic obstructive pulmonary disease	Franciscus Gasthuis	Recruiting	No outcome recorded
—	NCT04994574	Aug 2021 → Jul 2024	chronic obstructive pulmonary disease	Yonsei University	Completed	No outcome recorded
—	NCT04137029	Apr 2019 → Jul 2020	reactive airway disease	Federal State Budgetary Institution, Pulmonology Scientific Research Institute	Unknown	No outcome recorded
—	NCT03842839	Oct 2018 → Dec 2022	—	Guangzhou Institute of Respiratory Disease	Unknown	No outcome recorded
—	NCT03258749	Nov 2017 → Aug 2018	chronic obstructive pulmonary disease	Huashan Hospital	Unknown	No outcome recorded
—	NCT00706446	Jun 2008 → Jun 2010	asthma	Brigham and Women's Hospital	Terminated	No outcome recorded

Also used as a comparator or background therapy in 134 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials
Phase 1	NCT06254664 Background	Oct 2022 → Jul 2023	chronic obstructive pulmonary disease	Xiromed LLC	Completed	No outcome recorded
Phase 1	NCT04850144 Comparator	Apr → Oct 2021	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03400241 Comparator	Feb → Apr 2018	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT03097380 Comparator	Apr → Dec 2017	—	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02059434 Comparator	Sep 2013 → Oct 2014	asthma, chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT01355991 Comparator	Aug 2011 → Mar 2016	spinal cord injury	James J. Peters Veterans Affairs Medical Center	Unknown	No outcome recorded
Phase 1	NCT02231177 Comparator	Jun → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00568503 Comparator	Oct 2007 → Feb 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 1	NCT00532350 Comparator	Jul 2007 → Jan 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT01176903 Comparator	Aug → Nov 2010	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 1/2	NCT00871182 Comparator	Mar → Sep 2009	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 225 trials
Phase 2	NCT05838703 Comparator	May 2023 → May 2024	chronic obstructive pulmonary disease	Duke University	Withdrawn	No outcome recorded
Phase 2	NCT03937479 Background	May → Nov 2019	chronic obstructive pulmonary disease	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT03673670 Background	Jul → Nov 2018	chronic obstructive pulmonary disease	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT03084796 Comparator	Jul 2017 → May 2018	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT03118765 Comparator	Mar → Jul 2017	chronic obstructive pulmonary disease	Glenmark Specialty S.A.	Completed	No outcome recorded
Phase 2	NCT03028142 Background	Jan → Aug 2017	chronic obstructive pulmonary disease	Verona Pharma, Inc.	Completed	No outcome recorded
Phase 2	NCT02382510 Comparator	Apr 2015 → Mar 2016	asthma	Theron Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT01708057 Comparator	Oct → Dec 2012	chronic obstructive pulmonary disease	AstraZeneca	Terminated	No outcome recorded
Phase 2	NCT01543919 Background	Apr 2012 → Sep 2013	chronic obstructive pulmonary disease	Pfizer	Completed	No outcome recorded
Phase 2	NCT01587079 Comparator	Apr → Sep 2012	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01566773 Comparator	Mar → Aug 2012	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01498081 Comparator	Mar → Oct 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT01426009 Comparator	Aug → Dec 2011	chronic obstructive pulmonary disease	Sunovion Respiratory Development Inc.	Completed	No outcome recorded
Phase 2	NCT01372410 Comparator	Jul → Oct 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01085045 Comparator	Mar → Nov 2010	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 2	NCT01068613 Comparator	Jan → Aug 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00950807 Comparator	Sep 2009 → Mar 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00939211 Comparator	Jun → Nov 2009	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00868231 Comparator	Mar → Jul 2009	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00720499 Background	Jul 2008 → Feb 2009	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00535366 Background	Oct 2007 → Sep 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00501852 Comparator	Jul → Dec 2007	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00515502 Comparator	Jun → Nov 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02242279 Comparator	Jun → Dec 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT02242240 Background	Mar → Dec 2001	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT00463567 Comparator	Apr 2007 → Aug 2008	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 351 trials
Phase 3	NCT04208581 Background	Oct 2019 → Dec 2021	chronic obstructive pulmonary disease, respiratory failure	Peking University People's Hospital	Unknown	No outcome recorded
Phase 3	NCT03976713 Background	Jun 2019 → Jun 2020	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT03376932 Comparator	Jan 2019 → Feb 2021	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT03745261 Background	Jun 2018 → Dec 2019	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT03158311 Comparator	Feb 2018 → Jul 2019	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02676089 Comparator	Apr 2016 → May 2018	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT02629965 Comparator	Feb 2016 → Mar 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02518139 Comparator	Sep 2015 → Jun 2017	chronic obstructive pulmonary disease	Mylan Inc.	Completed	No outcome recorded
Phase 3	NCT02467452 Comparator	May 2015 → Jan 2017	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT02347072 Comparator	Feb → Aug 2015	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT02296138 Comparator	Jan 2015 → Mar 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02257385 Comparator	Oct 2014 → May 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02276222 Comparator	Oct 2014 → Feb 2016	chronic obstructive pulmonary disease	Sunovion Respiratory Development Inc.	Completed	No outcome recorded
Phase 3	NCT01899742 Comparator	Sep 2014 → Jul 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02207829 Comparator	Sep 2014 → May 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02165826 Background	May 2014 → Sep 2015	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01837927 Comparator	Apr 2014 → Apr 2016	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 3	NCT01911364 Comparator	Jan 2014 → Mar 2016	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01970878 Comparator	Nov 2013 → Mar 2015	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT01964352 Comparator	Nov 2013 → Oct 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01854645 Comparator	May 2013 → Feb 2015	chronic obstructive pulmonary disease	Pearl Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT01777334 Comparator	Jan → Sep 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01610037 Comparator	Oct 2012 → Feb 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01694771 Background	Sep 2012 → Aug 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01696058 Background	Sep 2012 → Oct 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01613326 Comparator	Jun 2012 → Jan 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01574651 Comparator	May 2012 → Apr 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01627327 Comparator	Apr → Dec 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01513460 Comparator	Apr 2012 → Dec 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01533922 Comparator	Mar 2012 → Nov 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01462929 Comparator	Nov 2011 → Mar 2012	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01490125 Comparator	Oct 2011 → Aug 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01395888 Comparator	Jun 2011 → Aug 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01316900 Comparator	Mar 2011 → Apr 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01316913 Comparator	Mar 2011 → Apr 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01294787 Comparator	Feb → Nov 2011	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01285492 Comparator	Jan 2011 → Sep 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01202188 Comparator	Sep 2010 → Feb 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01126437 Comparator	May 2010 → May 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01120691 Comparator	Apr 2010 → Jul 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01040689 Comparator	Jan 2010 → Jan 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01040728 Comparator	Jan 2010 → Jan 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00929110 Comparator	Jun 2009 → Apr 2011	chronic obstructive pulmonary disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00900731 Comparator	Jun 2009 → Mar 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00877383 Background	Apr 2009 → Feb 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00845728 Comparator	Mar 2009 → Jul 2012	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00846586 Background	Mar 2009 → Mar 2010	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00662740 Comparator	Apr → Nov 2008	chronic obstructive pulmonary disease	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 3	NCT00435760 Comparator	Feb → Aug 2007	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00308191 Background	Apr → May 2006	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 3	NCT00274066 Background	Oct 2002 → Sep 2003	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded

Phase 437 trials
Phase 4	NCT06282861 Comparator	Feb 2024 → Jan 2025	chronic obstructive pulmonary disease	Fundacio Privada Mon Clinic Barcelona	Terminated	No outcome recorded
Phase 4	NCT05113615 Comparator	Dec 2021 → May 2022	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT04061161 Comparator	Aug 2019 → Dec 2023	chronic obstructive pulmonary disease	University Medical Center Groningen	Completed	No outcome recorded
Phase 4	NCT03395002 Comparator	Mar 2018 → Apr 2020	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02546297 Comparator	Sep 2017 → Sep 2020	bronchiectasis	Shanghai Pulmonary Hospital, Shanghai, China	Unknown	No outcome recorded
Phase 4	NCT03275116 Comparator	Jul 2017 → Apr 2020	chronic obstructive pulmonary disease	Maastricht University Medical Center	Unknown	No outcome recorded
Phase 4	NCT03152149 Comparator	Jun 2017 → Nov 2019	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02853123 Comparator	Sep 2016 → Jul 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02988869 Comparator	Aug 2016 → Aug 2017	chronic obstructive pulmonary disease	Neutec Ar-Ge San ve Tic A.Ş	Completed	No outcome recorded
Phase 4	NCT02683109 Comparator	Mar 2016 → Jan 2017	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02603393 Comparator	Nov 2015 → Jul 2017	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02275481 Comparator	Nov 2014 → Sep 2016	chronic obstructive pulmonary disease	Sumitomo Pharma America, Inc.	Terminated	No outcome recorded
Phase 4	NCT02039050 Comparator	Feb 2014 → Jul 2015	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT02473237 Comparator	Apr 2013 → Jun 2015	chronic obstructive pulmonary disease	National Institute of Respiratory Diseases, Mexico	Completed	No outcome recorded
Phase 4	NCT01727024 Comparator	Apr 2013 → Nov 2015	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02566031 Comparator	Mar 2013 → Jun 2018	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01751113 Comparator	Feb → Nov 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01715311 Comparator	Nov 2012 → Sep 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT05506865 Comparator	Sep 2012 → Jan 2016	chronic obstructive pulmonary disease	National Institute of Respiratory Diseases, Mexico	Completed	No outcome recorded
Phase 4	NCT01663987 Comparator	Aug 2012 → May 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01662986 Comparator	Aug 2012 → Apr 2014	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01455129 Comparator	Nov 2011 → Aug 2016	chronic obstructive pulmonary disease	The First Affiliated Hospital of Guangzhou Medical University	Completed	No outcome recorded
Phase 4	NCT01466712 Background	Nov 2011 → Dec 2014	pulmonary emphysema	KU Leuven	Unknown	No outcome recorded
Phase 4	NCT01437748 Comparator	Aug 2011 → Sep 2014	chronic obstructive pulmonary disease	University of Milan	Completed	No outcome recorded
Phase 4	NCT01124422 Background	Jul 2010 → May 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01072396 Comparator	Feb 2010 → Nov 2011	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00864812 Comparator	Mar 2009 → Mar 2010	chronic obstructive pulmonary disease	The Korean Academy of Tuberculosis and Respiratory Diseases	Completed	No outcome recorded
Phase 4	NCT00975195 Background	Feb 2009 → Jul 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00784550 Comparator	Dec 2008 → Dec 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00563381 Comparator	Jan 2008 → Apr 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00546234 Comparator	Nov 2007 → Jan 2014	asthma	University of Alberta	Withdrawn	No outcome recorded
Phase 4	NCT00496470 Comparator	May 2007 → Jun 2008	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00424528 Comparator	Dec 2006 → Oct 2007	bronchitis, pulmonary emphysema	Sumitomo Pharma America, Inc.	Completed	No outcome recorded
Phase 4	NCT00996697 Comparator	Oct 2006 → Sep 2008	chronic obstructive pulmonary disease	Brian J Lipworth	Completed	No outcome recorded
Phase 4	NCT00412204 Comparator	Jun 2006 → Apr 2009	chronic obstructive pulmonary disease	McMaster University	Completed	No outcome recorded
Phase 4	NCT00394485 Background	May 2006 → Apr 2008	chronic obstructive pulmonary disease	Otsuka Pharmaceutical Co., Ltd.	Terminated	No outcome recorded
Phase 4	NCT01307189 Comparator	Apr 2005 → Aug 2010	chronic obstructive pulmonary disease	Laval University	Completed	No outcome recorded

Phase not applicable9 trials
—	NCT07058259 Background	Nov 2024 → Jun 2025 overdue	chronic obstructive pulmonary disease	Istanbul Medeniyet University	Active not recruiting	No outcome recorded
—	NCT06609941 Background	Jun 2024 → Jan 2025 overdue	asthma	Foundation University Islamabad	Recruiting	No outcome recorded
—	NCT05295355 Background	Jan 2021 → Sep 2024	chronic obstructive pulmonary disease	Guangzhou Institute of Respiratory Disease	Unknown	No outcome recorded
—	NCT03504527 Comparator	May → Nov 2018	bronchial disorder	Huashan Hospital	Unknown	No outcome recorded
—	NCT03083067 Background	Mar 2017 → Mar 2022	chronic obstructive pulmonary disease	Peking University First Hospital	Completed	No outcome recorded
—	NCT02790047 Background	Oct 2016 → Jan 2018	chronic obstructive pulmonary disease	Khon Kaen University	Unknown	No outcome recorded
—	NCT02257463 Comparator	Oct 2011 → Apr 2014	chronic obstructive pulmonary disease	Mansoura University	Completed	No outcome recorded
—	NCT02331940 Comparator	Mar 2010 → Dec 2013	chronic obstructive pulmonary disease	University of Crete	Completed	No outcome recorded
—	NCT00981851 Comparator	Sep 2009 → May 2011	cardiovascular disorder, chronic obstructive pulmonary disease	Radboud University Medical Center	Completed	No outcome recorded

Evidence & citations 24 cited values

Every value below carries the sentence it was read from. 341 sources stand behind the page.

Field	Value	Cited text
Known as	Tiotropium	“This pilot study was designed to evaluate the pharmacokinetic characteristics of fluticasone, salmeterol, and tiotropium after co-administration of HCP 0910 (Seretide 250...” NCT02441114 ↗ 278 “The investigators will compare the reduction in Borg dyspnea score during the 3-min constant rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg...” NCT02567214 ↗ “The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination...” NCT02030535 ↗ “Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive...” NCT03265145 ↗ “Tiotropium, a once-daily long-acting anticholinergic agent, has been shown to be an efficacious and safe add-on treatment for adults with symptomatic asthma, despite treatment...” PMID 25081651 ↗ Jul 2014 “patients were randomized to receive either tiotropium 5 μg or a fixed-dose combination of tiotropium 5 μg with olodaterol 2 μg, 5 μg, or 10 μg, delivered once daily via the...” PMID 30843141 ↗ Mar 2019 “Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent...” NCT02799784 ↗ “Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics:...” NCT02165826 ↗ “An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of...” NCT03097380 ↗ “Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.” NCT03169504 ↗ “Inhalation of 4 puffs of 2,5 µg of a long-acting muscarinic antagonist (LAMA-tiotropium) administered via a spacer device” NCT05927155 ↗ “Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.” NCT03095456 ↗ “Inhaled Fenotereol,Ipratroium Plus Beclomethasone Versus Salmeterol,Tiotropium Plus Fluticasone” NCT05748977 ↗ “Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days” NCT01587079 ↗ “inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)” NCT03504527 ↗ “Tiotropium is a once-daily, long-acting anticholinergic bronchodilator” PMID 25188297 ↗ Sep 2014 “Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients” NCT00274508 ↗ “Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler” NCT02276222 ↗ “Spiriva® (tiotropium) 18 mcg, one inhalation once daily” NCT00496470 ↗ “18 μg Tiotropium [Spiriva® HandiHaler®]” NCT02254174 ↗ “Tiotropium 18 µg inhalation capsule” NCT02172807 ↗ “Tiotropium (Anticholinergic)” NCT06609941 ↗ “Tiotropium(inhaler)” NCT02790047 ↗ “Tiotropium” NCT04179461 ↗ “Tiotropium” NCT03662711 ↗ NCT01911364 ↗ NCT00871182 ↗ NCT03055988 ↗ NCT05295355 ↗ NCT01316900 ↗ NCT04648813 ↗ NCT01316380 ↗ NCT03158311 ↗ NCT01455129 ↗ NCT00870896 ↗ NCT03302065 ↗ NCT00350207 ↗ NCT00783250 ↗ NCT00563381 ↗ NCT01490125 ↗ NCT01964352 ↗ NCT00662792 ↗ NCT02988869 ↗ NCT01483625 ↗ NCT00239499 ↗ NCT00662740 ↗ NCT03028142 ↗ NCT01431287 ↗ NCT02627625 ↗ NCT00168844 ↗ NCT01431274 ↗ NCT01233284 ↗ NCT00325169 ↗ NCT00981851 ↗ NCT05506865 ↗ NCT00168831 ↗ NCT03425617 ↗ NCT01040728 ↗ NCT01040689 ↗ NCT03275116 ↗ NCT01610037 ↗ NCT02518139 ↗ NCT00939211 ↗ NCT00877383 ↗ NCT01656005 ↗ NCT00578968 ↗ NCT03258749 ↗ NCT00996697 ↗ NCT06679465 ↗ NCT01040403 ↗ NCT02125734 ↗ NCT01777334 ↗ NCT02853123 ↗ NCT01959516 ↗ NCT01703845 ↗ NCT02203474 ↗ NCT01785433 ↗ NCT02173691 ↗ NCT00975195 ↗ NCT02039050 ↗ NCT01397890 ↗ NCT02085161 ↗ NCT03937479 ↗ NCT04990167 ↗ NCT06254664 ↗ NCT01112241 ↗ NCT02566031 ↗ NCT01120691 ↗ NCT00387088 ↗ NCT01395888 ↗ NCT02473237 ↗ NCT02039011 ↗ NCT00239460 ↗ NCT00501852 ↗ NCT00388882 ↗ NCT00523991 ↗ NCT00868231 ↗ NCT02603393 ↗ NCT00668772 ↗ NCT00525512 ↗ NCT00239447 ↗ NCT01222533 ↗ NCT01708057 ↗ NCT03155204 ↗ NCT01899742 ↗ NCT03240575 ↗ NCT00772538 ↗ NCT01462929 ↗ NCT03474081 ↗ NCT04223843 ↗ NCT01309139 ↗ NCT01340209 ↗ NCT03945344 ↗ NCT02175342 ↗ NCT02275481 ↗ NCT01574651 ↗ NCT01498081 ↗ NCT01277523 ↗ NCT00394485 ↗ NCT02172794 ↗ NCT02172781 ↗ NCT01533935 ↗ NCT00274014 ↗ NCT02172508 ↗ NCT01307189 ↗ NCT00845728 ↗ NCT00557700 ↗ NCT01536262 ↗ NCT02207829 ↗ NCT01285492 ↗ NCT02172469 ↗ NCT00274040 ↗ NCT02172456 ↗ NCT03673670 ↗ NCT00239434 ↗ NCT02629965 ↗ NCT02172443 ↗ NCT02059434 ↗ NCT02172430 ↗ NCT02172417 ↗ NCT02796677 ↗ NCT02296138 ↗ NCT01533922 ↗ NCT02172391 ↗ NCT02172378 ↗ NCT01437748 ↗ NCT00846586 ↗ NCT04061161 ↗ NCT02172339 ↗ NCT02231177 ↗ NCT00274053 ↗ NCT02172326 ↗ NCT03246581 ↗ NCT00274066 ↗ NCT02172300 ↗ NCT02172287 ↗ NCT01119937 ↗ NCT01854645 ↗ NCT00274092 ↗ NCT00673478 ↗ NCT00463567 ↗ NCT01613326 ↗ NCT01202188 ↗ NCT00365560 ↗ NCT01257230 ↗ NCT07541378 ↗ NCT04994574 ↗ NCT00274521 ↗ NCT01969721 ↗ NCT01794780 ↗ NCT00929110 ↗ NCT00405236 ↗ NCT03478683 ↗ NCT00239421 ↗ NCT04520230 ↗ NCT00530842 ↗ NCT00128440 ↗ NCT03478696 ↗ NCT03964207 ↗ NCT01012765 ↗ NCT01837927 ↗ NCT00144196 ↗ NCT00122434 ↗ NCT00144326 ↗ NCT00864812 ↗ NCT01634113 ↗ NCT01355991 ↗ NCT00106821 ↗ NCT00144339 ↗ NCT01970878 ↗ NCT00274547 ↗ NCT00274560 ↗ NCT00274573 ↗ NCT02257385 ↗ NCT01922271 ↗ NCT03842839 ↗ NCT00532350 ↗ NCT00999908 ↗ NCT00615459 ↗ NCT01513460 ↗ NCT00257452 ↗ NCT01466712 ↗ NCT00157235 ↗ NCT00412204 ↗ NCT02541006 ↗ NCT01085045 ↗ NCT02254174 ↗ NCT03118765 ↗ NCT00335621 ↗ NCT01727024 ↗ NCT00776984 ↗ NCT02682862 ↗ NCT02177305 ↗ NCT02331940 ↗ NCT01634152 ↗ NCT01634139 ↗ NCT01525615 ↗ NCT00435760 ↗ NCT00359788 ↗ NCT02872090 ↗ NCT00152984 ↗ NCT02259959 ↗ NCT02006732 ↗ NCT01152450 ↗ NCT00950807 ↗ NCT02238119 ↗ NCT01696071 ↗ NCT01696058 ↗ NCT00680056 ↗ NCT04231214 ↗ NCT02683109 ↗ NCT00292448 ↗ NCT02812862 ↗ NCT03376932 ↗ NCT03152149 ↗ NCT01068613 ↗ NCT01179347 ↗ NCT01294787 ↗ NCT00277264 ↗ NCT00535366 ↗ NCT04850144 ↗ NCT01694771 ↗ NCT01176903 ↗ NCT02622243 ↗ NCT02676297 ↗ NCT02676089 ↗ NCT00279019 ↗ NCT00274534 ↗ NCT02546349 ↗ NCT01372410 ↗ NCT00422604 ↗ NCT01715311 ↗ NCT05165485 ↗ NCT01762800 ↗ NCT01172925 ↗ NCT01172808 ↗ NCT01383499 ↗ NCT01126437 ↗ NCT00281567 ↗ NCT02066298 ↗ NCT01559116 ↗ NCT01172821 ↗ NCT02573155 ↗ NCT00424528 ↗ NCT01693003 ↗ NCT01566773 ↗ NCT01290874 ↗ NCT00515502 ↗ NCT03395002 ↗ NCT02683668 ↗ NCT02242240 ↗ NCT02242279 ↗ NCT00546234 ↗ NCT02242253 ↗ NCT01072396 ↗ NCT02382510 ↗ NCT00900731 ↗ NCT02969317 ↗ NCT02242266 ↗
Known as	Ba 79 BR	“The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation” NCT02172430 ↗
Known as	Ba679BR	“A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind,...” NCT02172807 ↗ 3 “Tiotropium (Ba679 BR)” NCT02172287 ↗ NCT02172352 ↗ NCT00292448 ↗
Known as	Bromuro de Tiotropio	“The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of...” NCT00144326 ↗ 2 “daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.” NCT00144339 ↗ “tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio)” NCT00157235 ↗
Known as	GSP304	“GSP304 (tiotropium bromide) Inhalation Solution” NCT03118765 ↗
Known as	Neng Beile	“Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）” NCT05295355 ↗
Known as	Si Lihua	“Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）” NCT05295355 ↗
Known as	Spiriva	“The purpose of the study is to determine the efficacy and safety of the combination of ADVAIR DISKUS® 250/50mcg (FLUTICASONE PROPIONATE/SALMETEROL COMBINATION PRODUCT) plus...” NCT00784550 ↗ 42 “The investigators will compare the reduction in Borg dyspnea score during the 3-min constant rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg...” NCT02567214 ↗ “The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of...” NCT00144326 ↗ “The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in...” NCT00274053 ↗ “To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of...” NCT00274066 ↗ “Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule,...” NCT03745261 ↗ “daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.” NCT00144339 ↗ “tiotropium 18 μg, formulated as inhalation powder in the hard gelatine capsule and delivered via the HandiHaler® (Spiriva®) following single dose inhalation” NCT02242266 ↗ “Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®)” NCT02467452 ↗ “Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD” NCT00239447 ↗ “a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ “Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.” NCT03095456 ↗ “Tiotropium (Spiriva, Boehringer Ingelheim), a long-acting inhaled anticholinergic bronchodilator” NCT02683668 ↗ “Tiotropium (Spiriva®) is a once-daily inhaled anticholinergic for the treatment of COPD.” NCT00239421 ↗ “long acting bronchodilators "foradil/spiriva" or combined LABD and inhaled steroids” NCT02257463 ↗ “A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)” NCT00257452 ↗ “tiotropium Handihaler® (Spiriva®) 18μg once daily for a duration of 4 weeks” NCT03964207 ↗ “Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler” NCT00281567 ↗ “Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients” NCT00274508 ↗ “Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)” NCT02347072 ↗ “tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule)” NCT00292448 ↗ “Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)” NCT00668772 ↗ “tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio)” NCT00157235 ↗ “plus Spiriva HandiHaler (tiotropium 18 mcg) once daily” NCT03478683 ↗ “following treatment with tiotropium bromide (Spiriva)” NCT00274027 ↗ “Tiotropium (Spiriva) + Salbutamol (Ventolin)” NCT00981851 ↗ “Tiotropium (Spiriva) Rehabilitation Study” NCT00274521 ↗ “18 μg of tiotropium bromide \[Spiriva®\]” NCT01112241 ↗ “Spiriva capsules inhaled via HandiHaler” NCT04850144 ↗ “Spiriva HandiHaler (tiotropium 18 mcg)” NCT03478696 ↗ “tiotropium (Spiriva, 18 µg q.d.)” NCT00239499 ↗ “Tiotropium (Spiriva®)” NCT06679465 ↗ “Tiotropium (Spiriva®)” NCT00277264 ↗ “Tiotropium, Spiriva®” NCT00662740 ↗ “tiotropium (Spiriva)” NCT00144196 ↗ NCT06282861 ↗ NCT01644734 ↗ NCT02263976 ↗ NCT00274079 ↗ NCT03118765 ↗ NCT02254174 ↗ NCT02546297 ↗ NCT02813200 ↗
Known as	Spiriva Handihaler	“a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®]” NCT02254174 ↗ 8 “Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days” NCT01085045 ↗ “open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01854645 ↗ “Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01970878 ↗ “tiotropium (delivered by the Handihaler® as Spiriva Handihaler®)” NCT01696058 ↗ “Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily)” NCT01072396 ↗ “Open-label drug also known as Spiriva HandiHaler” NCT01124422 ↗ “18 mcg tiotropium (Spiriva HandiHaler) daily” NCT00525512 ↗ NCT03219866 ↗
Known as	Spiriva Respimat	“Tiotropium (Spiriva® Respimat®, Boehringer Ingelheim International) is approved as a once-daily maintenance treatment of asthma” NCT04990167 ↗ 4 “tiotropium Respimat® (Spiriva® Respimat®) 5 microgram (μg) once daily for a duration of 4 weeks” NCT03964207 ↗ “Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)” NCT02347072 ↗ “tiotropium bromide monohydrate (Spiriva Respimat)” NCT04648813 ↗ NCT03358147 ↗
Known as	SpirivaTM	“Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily” NCT01397890 ↗
Known as	T18GEL	“18 µg Tiotropium (T18GEL) inhalation powder plus 50 µg Salmeterol MDPI (S\_DPI) twice daily (BID)” NCT00662792 ↗
Known as	TIO	“The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD.” PMID 27103795 ↗ Apr 2016 5 “with tiotropium bromide (TIO), 18 μg, on aPWV.” PMID 25058845 ↗ Dec 2014 “compared with tiotropium (TIO) 18 mcg/day” PMID 27796912 ↗ Oct 2016 “antimuscarinic tiotropium bromide (TIO)” PMID 20580216 ↗ Jun 2010 “once-daily tiotropium (TIO) 18 µg” PMID 25841237 ↗ Apr 2015 “Tiotropium 18 μg (TIO 18 μg)” NCT02796677 ↗
Known as	Tio18GEL	“18 µg Tiotropium (Tio18GEL) inhalation powder” NCT00662792 ↗ 1 “tiotropium (Tio18GEL)” NCT00668772 ↗
Known as	Tiotropium Bromide	“A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the...” NCT01483625 ↗ 72 “Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “The objective of this trial is to evaluate whether the effect of one year (48 weeks) treatment with inhaled tiotropium bromide (Spiriva® - 18 µg once daily) on the change in...” NCT00277264 ↗ “The objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of...” NCT00274014 ↗ “A total of 839 patients with COPD who satisfied the eligibility criteria were randomly assigned (1:1) to receive a once daily inhaled capsule of either tiotropium bromide (18...” PMID 24549160 ↗ Feb 2014 “Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration...” NCT01120691 ↗ “Proof of Concept Evaluation of Drug-Device Interaction With Aclidinium Bromide Via Genuair® and Tiotropium Bromide Via HandiHaler® in COPD Using Impulse Oscillometry” NCT02039050 ↗ “Tiotropium bromide, long-acting muscarinic antagonist (LAMA). Administered as 2.5 μg per actuation, 2 inhalations once daily via Respimat inhaler for 28 days.” NCT07541378 ↗ “Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®)” NCT02467452 ↗ “single inhaled doses of GSK573719 (250, 500 and 1000 μg) and Tiotropium Bromide (18 μg) Via DPI in COPD Patients.” NCT00515502 ↗ “1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer.” NCT00981851 ↗ “The objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1” NCT00239460 ↗ “Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler” NCT01257230 ↗ “Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks” NCT04208581 ↗ “inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)” NCT03504527 ↗ “Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days” NCT01085045 ↗ “0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks” NCT01543919 ↗ “Tiotropium Bromide 18µg (Oral Inhalation, Delivered by the HandiHaler®)” NCT01040689 ↗ “Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01970878 ↗ “open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)” NCT01854645 ↗ “Tiotropium bromide (Spiriva) capsule 18μg once daily inhaled.” NCT03842839 ↗ “once-daily tiotropium bromide (18 μg) versus placebo” PMID 25289942 ↗ Nov 2014 “Tiotropium Bromide Spray (Si Lihua ® Neng Beile ®）” NCT05295355 ↗ “GSP304 (tiotropium bromide) Inhalation Solution” NCT03118765 ↗ “with tiotropium bromide (TIO), 18 μg, on aPWV.” PMID 25058845 ↗ Dec 2014 “Spiriva® Handihaler® (Tiotropium Bromide)” NCT01566773 ↗ “with tiotropium bromide 18 μg once daily” PMID 24124358 ↗ Oct 2013 “18 μg of tiotropium bromide \[Spiriva®\]” NCT01112241 ↗ “antimuscarinic tiotropium bromide (TIO)” PMID 20580216 ↗ Jun 2010 “tiotropium bromide 2.5µg once daily” NCT01233284 ↗ “inhaled tiotropium bromide” NCT02172378 ↗ “Drug: Tiotropium Bromide” NCT04990167 ↗ “Drug: Tiotropium bromide” NCT01437748 ↗ “Drug: Tiotropium Bromide” NCT04061161 ↗ “Drug: Tiotropium bromide” NCT00563381 ↗ “Drug: tiotropium bromide” NCT00412204 ↗ NCT01426009 ↗ NCT01316913 ↗ NCT01662986 ↗ NCT01751113 ↗ NCT04780984 ↗ NCT03745261 ↗ NCT01663987 ↗ NCT05113615 ↗ NCT02347072 ↗ NCT00565266 ↗ NCT01122680 ↗ NCT00308191 ↗ NCT02172534 ↗ NCT00274027 ↗ NCT00555022 ↗ NCT00706446 ↗ NCT01465906 ↗ NCT00496470 ↗ NCT00274508 ↗ NCT00784550 ↗ NCT00528996 ↗ NCT00239408 ↗ NCT03083067 ↗ NCT00568503 ↗ NCT01124422 ↗ NCT00361959 ↗ NCT00737100 ↗ NCT03976713 ↗ NCT02259946 ↗ NCT02586649 ↗ NCT03199976 ↗ NCT03084796 ↗ NCT00720499 ↗ NCT04137029 ↗ NCT00696020 ↗ NCT01627327 ↗ NCT05838703 ↗
Known as	Tiotropium Bromide Monohydrate	“Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent...” NCT02799784 ↗ 4 “Micronized Tiotropium Bromide Monohydrate 22.5 mcg” NCT02441114 ↗ “tiotropium bromide monohydrate (Spiriva Respimat)” NCT04648813 ↗ NCT05246046 ↗ NCT03400241 ↗
Known as	Tiotropium Bromide Powder for Inhalation (Spiriva)	“Tiotropium Bromide Powder for Inhalation (Spiriva®)” NCT03169504 ↗
Known as	Tiotropium BromideInhalation Aerosol Suspension	“Tiotropium BromideInhalation Aerosol Suspension” NCT05295355 ↗
Known as	Tiotropium Respimat	“Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study” PMID 24890738 ↗ Jun 2014
Known as	tiotropium: Spiriva	“tiotropium: Spiriva” NCT00864812 ↗
Known as	Trimbow	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05495698 ↗
Action	Inhibit	“the long-acting anticholinergic tiotropium” PMID 21807250 ↗ Aug 2011
Modality	Other / unclassified	“once-daily long-acting anticholinergic” PMID 27812637 ↗ Sep 2016
Route	Inhaled	“Tiotropium Bromide Inhalation Powder” NCT00106821 ↗